Comparative Pharmacology
Head-to-head clinical analysis: FLUDARA versus ZYNLONTA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUDARA versus ZYNLONTA.
FLUDARA vs ZYNLONTA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fludarabine is a purine nucleotide analog that inhibits DNA synthesis by interfering with ribonucleotide reductase and DNA polymerase, leading to cell death in dividing lymphocytes.
ZYNLONTA (loncastuximab tesirine-lpyl) is a CD19-directed antibody-drug conjugate (ADC) consisting of a humanized anti-CD19 monoclonal antibody conjugated via a cleavable linker to a pyrrolobenzodiazepine (PBD) dimer cytotoxin. Upon binding to CD19-expressing cells, the conjugate is internalized and the linker is cleaved, releasing the PBD dimer, which crosslinks DNA and induces cell death.
25 mg/m^2 intravenously over 30 minutes daily for 5 consecutive days every 28 days.
0.15 mg/kg intravenously every 3 weeks, up to a maximum of 9 mg per dose, until disease progression or unacceptable toxicity.
None Documented
None Documented
Clinical Note
moderateFludarabine + Digoxin
"Fludarabine may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateFludarabine + Digitoxin
"Fludarabine may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateFludarabine + Deslanoside
"Fludarabine may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateFludarabine + Acetyldigitoxin
"Fludarabine may decrease the cardiotoxic activities of Acetyldigitoxin."
Fludarabine phosphate: 0.7-1 h (rapid dephosphorylation). Active metabolite 2-fluoro-ara-A: terminal t1/2 20-30 h (up to 40 h in renal impairment).
Terminal elimination half-life (t½) is approximately 0.6 hours (range 0.3–1.0 hours) for the intact antibody–drug conjugate, reflecting rapid clearance; the unconjugated payload (SG3199) has a longer t½ of approximately 1–2 hours.
Renal: 60% excreted unchanged in urine; biliary/fecal: <5% as metabolites.
Primarily eliminated via biliary/fecal route (approximately 71% of administered dose recovered in feces as unchanged drug), with renal excretion accounting for a minor fraction (<10% of dose as unchanged drug in urine).
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent